Comparison between Innokaiz India IPO and Remus Pharmaceuticals IPO.
Innokaiz India IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Remus Pharmaceuticals IPO is a SME Bookbuilding proposed to list at NSE SME.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Gretex Corporate Services Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Gretex Share Broking Pvt.Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Innokaiz India IPO is up to ₹20.11 Cr whereas the issue size of the Remus Pharmaceuticals IPO is up to ₹45.29 Cr. The final issue price of Innokaiz India IPO is ₹78.00 per share and of Remus Pharmaceuticals IPO is ₹1,229.00 per share.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹76.00 per share | ₹1,150.00 per share |
| Issue Price (Upper) | ₹78.00 per share | ₹1,229.00 per share |
| Issue Price (Final) | ₹78.00 per share | ₹1,229.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 1600 shares | 100 shares |
| Fresh Issue Size | 25,77,600 shares | 3,68,500 shares |
| Fresh Issue Size (Amount) | up to ₹20.11 Cr | up to ₹45.29 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 25,77,600 shares | 3,68,500 shares |
| Issue Size Total (Amount) | up to ₹20.11 Cr | up to ₹45.29 Cr |
Innokaiz India IPO opens on Apr 28, 2023, while Remus Pharmaceuticals IPO opens on May 17, 2023. The closing date of Innokaiz India IPO and Remus Pharmaceuticals IPO is May 03, 2023, and May 19, 2023, respectively.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Apr 27, 2023 | May 16, 2023 |
| Issue Open | Apr 28, 2023 | May 17, 2023 |
| Issue Close | May 03, 2023 | May 19, 2023 |
| Basis Of Allotment (Tentative) | May 08, 2023 | May 24, 2023 |
| Initiation of Refunds (Tentative) | May 09, 2023 | May 25, 2023 |
| Credit of Share (Tentative) | May 10, 2023 | May 26, 2023 |
| Listing date (Tentative) | May 11, 2023 | May 29, 2023 |
| Anchor Lockin End date 1 | Jun 07, 2023 | Jun 23, 2023 |
| Anchor Lockin End date 2 | Aug 06, 2023 | Aug 22, 2023 |
Innokaiz India IPO P/E ratio is , as compared to Remus Pharmaceuticals IPO P/E ratio of 21.09.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 98.00 | 92.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.99 | 68.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 21.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹181.03 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 71.44% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 69.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹33.86 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 52.64% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Innokaiz India IPO Retail Individual Investors (RII) are offered 9,02,400 shares while in Remus Pharmaceuticals IPO retail investors are offered 9,02,400 shares. Qualified Institutional Buyers (QIB) are offered 5,15,200 shares in Innokaiz India IPO and 73,700 shares in Remus Pharmaceuticals IPO.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reserveration | 7,72,800 shares | 1,10,500 shares |
| Market Maker Reserveration | 1,36,000 shares | 19,500 shares |
| QIB | 5,15,200 shares | 73,700 shares |
| NII | 3,87,200 shares | 55,300 shares |
| RII | 9,02,400 shares | 1,29,000 shares |
| Employee | ||
| Others | ||
| Total | 25,77,600 shares | 3,68,500 shares |
Innokaiz India IPO subscribed 95.08x in total, whereas Remus Pharmaceuticals IPO subscribed 57.21x.
| Innokaiz India IPO | Remus Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 23.93x | 10.75x |
| NII (times) | 303.92x | 229.31x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 46.10x | 49.81x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 95.08x | 57.21x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
